Cargando…

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales:	Dalovisio, A., Bahlis, N., Raje, N., Costello, C., Dholaria, B., Solh, M., Levy, M., Tomasson, M., Dube, H., Damore, M., Jiang, S., Basu, C., Skoura, A., Chan, E., Trudel, S., Jakubowiak, A., Chu, M., Gasparetto, C., Sebag, M., Lesokhin, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430032/ http://dx.doi.org/10.1097/01.HS9.0000846460.44039.3d

Ejemplares similares

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
por: Bahlis, Nizar J., et al.
Publicado: (2023)

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3
por: Lesokhin, A. M., et al.
Publicado: (2022)

S196: ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3
por: Mohty, Mohamad, et al.
Publicado: (2023)

P870: EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISMM STUDIES
por: Manier, Salomon, et al.
Publicado: (2023)

Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
por: Lesokhin, Alexander M., et al.
Publicado: (2023)

T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma
por: Verkleij, Christie P.M., et al.
Publicado: (2020)

T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA
por: van de Donk, Niels W.C.J., et al.
Publicado: (2023)

P880: EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Leleu, Xavier, et al.
Publicado: (2023)

P906: GENOMIC ANALYSIS TO IDENTIFY DETERMINANTS OF INHERENT RESPONSE AND RESISTANCE TO ELRANATAMAB IN MAGNETISMM-3 COHORT A
por: Rodríguez-Otero, Paula, et al.
Publicado: (2023)

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas
por: Martens, Anne W.J., et al.
Publicado: (2022)

P907: EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROM MAGNETISMM-3
por: Touzeau, Cyrille, et al.
Publicado: (2023)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
por: Lin, Y., et al.
Publicado: (2022)

P930: ELRANATAMAB MONOTHERAPY OR IN COMBINATION WITH DARATUMUMAB VS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: PHASE 3 MAGNETISMM-5 STUDY, PART 2
por: Leleu, Xavier, et al.
Publicado: (2023)

897. Patients with Mpox, Minnesota, 2022
por: Lehnertz, Nicholas, et al.
Publicado: (2023)

Elrexfio™ (elranatamab-bcmm): The game-changer in treatment of multiple myeloma
por: Rais, Taruba, et al.
Publicado: (2023)

Piano trios, D. 929, D. 897
por: Schubert, Franz, 1797-1828
Publicado: (1989)

Vacuum observations during the long term vacuum stability run 897
por: Calder, R, et al.
Publicado: (1978)

LB897 The risk of COVID-19 infection in patients with alopecia areata
por: Oulee, A., et al.
Publicado: (2022)

Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma
por: Frigault, Matthew J., et al.
Publicado: (2022)

LASSBio-897 Reduces Lung Injury Induced by Silica Particles in Mice: Potential Interaction with the A(2A) Receptor
por: Carvalho, Vinicius F., et al.
Publicado: (2017)

Effects of Hypochlorous Acid Solutions on Venous Leg Ulcers (VLU): Experience With 1249 VLUs in 897 Patients
por: Bongiovanni, Cheryl M.
Publicado: (2016)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

The wooden fighting ship in the Royal Navy, A.D. 897-1860
por: Archibald, E. H. H. (Edward H. H.)
Publicado: (1968)

Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case
por: Mutlu, Yasa Gul, et al.
Publicado: (2023)

Hospital Outcomes in Antepartum Mental Disorders: A Study on 897,397 Pregnant Inpatients
por: Bhimanadham, Narmada N., et al.
Publicado: (2019)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

Expression of TNF-α, April and BCMA in Behcet's Disease
por: Shaker, Olfat G., et al.
Publicado: (2014)

897. Prediction of Surgical Site Infections in Colon Surgery in Belo Horizonte Hospitals
por: de Souza, Flávio Henrique Batista, et al.
Publicado: (2020)

PB2032: MAGNETISMM-9: AN OPEN-LABEL, MULTICENTER, NON-RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Fonseca, R., et al.
Publicado: (2022)

POS-897 A CASE OF DE NOVO NELL-1 MEMBRANOUS NEPHROPATHY POST COVID-19 VACCINATION
por: GARG, A., et al.
Publicado: (2022)

Wild type and K897T polymorphisms of the hERG gene: modeling the APD in Caucasians
por: Glinka, Anna, et al.
Publicado: (2012)

Phosphorylation of T897 in the dimerization domain of Gemin5 modulates protein interactions and translation regulation
por: Francisco-Velilla, Rosario, et al.
Publicado: (2022)

An International Reference Consensus Genetic Map with 897 Marker Loci Based on 11 Mapping Populations for Tetraploid Groundnut (Arachis hypogaea L.)
por: Gautami, Bhimana, et al.
Publicado: (2012)

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN
por: Munawar, U., et al.
Publicado: (2023)

P962: CHANGE IN SOLUBLE BCMA LEVEL MAY BE A SURROGATE MARKER OF EARLY RESPONSE TO THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PRELIMINARY RESULTS FROM A PHASE I STUDY OF CEVOSTAMAB
por: Nakamura, R., et al.
Publicado: (2022)

P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Weisel, Katja, et al.
Publicado: (2023)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Genome-Wide Identification and Functional Characterization of β-Agarases in Vibrio astriarenae Strain HN897
por: Liu, Yupeng, et al.
Publicado: (2020)

Redirecting the focus of cancer immunotherapy to premalignant conditions
por: Young, M. Rita I.
Publicado: (2017)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1hkdjar5pv8bdha8cpf8i348lh